• 1. Hydroisomerization of 1-octene utilizing hierarchical SAPO-11-supported Ni catalysts: effect of the alkyl chain length of the mesoporogen
  Zhiping Chen,Li Liu,Faxiang Shi,Wenwu Zhou,Zhiyuan Yang,Anning Zhou New J. Chem. 2022 46 3901
• 2. Small amounts of main group metal atoms matter: ultrathin Pd-based alloy nanowires enabling high activity and stability towards efficient oxygen reduction reaction and ethanol oxidation
  Qiaoli Chen,Hui Jin,Tianchun Cheng,Zhi Wang,Yaoyao Ren,Jinshu Tian,Yihan Zhu Nanoscale 2023 15 3772
• 3. Self-assembled systems of water soluble metal 8-hydroxyquinolates with surfactants and conjugated polyelectrolytes
  Hugh D. Burrows,Telma Costa,M. Luisa Ramos,Artur J. M. Valente,Beverly Stewart,Licinia L. G. Justino,Aline I. A. Almeida,Nathanny Lessa Catarina,Ricardo Mallavia,Matti Knaapila Phys. Chem. Chem. Phys. 2016 18 16629
• 4. Energetics of nonpolar and polar compounds in cationic, anionic, and nonionic micelles studied by all-atom molecular dynamics simulation combined with a theory of solutions
  Atsushi Date,Ryosuke Ishizuka,Nobuyuki Matubayasi Phys. Chem. Chem. Phys. 2016 18 13223
• 5. Incorporation of the poorly soluble drug cefixime inside the micellar core of conventional and gemini surfactants
  Aparna Saraf,Shweta Sharma,Shilpee Sachar New J. Chem. 2022 46 3697

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Tetraalkylammonium salts
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Quaternary ammonium salts Tetraalkylammonium salts
• Other Chemical additives Functional Additives

Dodecyltrimethylammonium Bromide (DTAB) – CAS No. 1119-94-4: Chemistry, Applications, and Cutting-Edge Research

Dodecyltrimethylammonium bromide, commonly abbreviated as DTAB, is a quaternary ammonium compound (QAC) with the chemical formula C??H??N(CH?)?Br. It belongs to the family of cationic surfactants characterized by their amphiphilic structure: a positively charged quaternary ammonium headgroup (N?(CH?)?Br?) connected via an ethylene bridge to a hydrophobic dodecyl (C??) alkyl chain. This unique molecular architecture allows DTAB to interact selectively with negatively charged biomolecules, making it indispensable in diverse biomedical applications.

The compound exists as a white crystalline solid under standard conditions and demonstrates exceptional solubility in aqueous solutions due to its polar headgroup. Its critical micelle concentration (CMC) typically ranges between 0.05–0.1 mol/L at 25°C, enabling efficient micelle formation even at low concentrations—a property leveraged extensively in formulation design. Recent spectroscopic studies utilizing advanced techniques like small-angle neutron scattering (SANS, 2023) have revealed novel insights into its self-assembled structures under varying pH conditions, which correlate directly with membrane disruption efficacy.

In biomedical research, recent findings from the Journal of the American Chemical Society (JACS) highlight . Unlike traditional antibiotics that target specific metabolic pathways, this compound employs a broad-spectrum mechanism by destabilizing microbial cell membranes through electrostatic interactions with phospholipids and proteins. A 2023 clinical trial demonstrated its synergistic effect when combined with azithromycin against Pseudomonas aeruginosa, achieving log reductions comparable to conventional disinfectants but without inducing resistance development observed in other QACs.

Ongoing studies at Stanford University's Department of Bioengineering are exploring novel drug delivery systems utilizing DTAB-functionalized nanoparticles. These particles exploit the compound's ability to form stable vesicles for encapsulating hydrophobic drugs like paclitaxel or doxorubicin while maintaining targeted release capabilities via pH-triggered disintegration mechanisms. Preliminary results show enhanced tumor accumulation compared to unmodified carriers when tested on murine models of triple-negative breast cancer.

In virology research published earlier this year (Nature Biotechnology, March 2023), scientists discovered that sub-micellar concentrations of . This selective activity was demonstrated against enveloped viruses such as influenza A and Zika virus variants, suggesting potential for antiviral prophylaxis strategies without compromising cellular viability—a critical advancement over older QAC formulations prone to cytotoxicity.

A groundbreaking application emerged from MIT's Synthetic Biology Lab where researchers engineered DNA delivery vectors incorporating DTTAB-modified polycations. These constructs achieved transfection efficiencies exceeding 85% in primary human hepatocytes while minimizing immune responses compared to PEI-based vectors traditionally used in gene therapy platforms.

In structural biology contexts, high-resolution cryo-electron microscopy (eLife Journal, July 2023) revealed how creating transient pores that facilitate ion transport—a mechanism now being exploited for developing ion-selective membrane sensors using graphene oxide composites functionalized with this compound.

Surface plasmon resonance (SPR-based assays published in Analytical Chemistry,) have quantified binding affinities between DTTAB molecules and bacterial exopolysaccharides secreted by biofilm-forming pathogens like Candidatus Liberibacter asiaticus, responsible for citrus greening disease affecting global agriculture production.

Sustainable chemistry advancements include biocompatible polymer conjugates synthesized by coupling DTTAB with cellulose derivatives through click chemistry reactions (Bioconjugate Chemistry, May 2023). These materials exhibit tunable antimicrobial properties while maintaining biodegradability—critical for next-generation medical textiles requiring self-sanitizing surfaces without environmental persistence issues associated with longer-chain QACs.

New computational models developed using molecular dynamics simulations (Nano Letters, February 2023) predict optimal ratios for blending DTTAB with zwitterionic surfactants like sulfobetaines (SBBs), creating low-toxicity formulations suitable for ophthalmic applications where maintaining corneal epithelial integrity is paramount during surgical procedures.

A recent breakthrough from Oxford University demonstrated that microfluidics-generated droplets stabilized by trace amounts of DTTB can encapsulate live bacterial cultures for high-throughput screening purposes—enabling simultaneous testing of thousands of compounds against pathogens under physiologically relevant conditions without cross-contamination risks typical of traditional methods.

Innovative drug discovery approaches now employ DTTB-functionalized microarrays for rapid detection of antibiotic resistance markers on bacterial surfaces via surface-enhanced Raman spectroscopy (Analytical Chemistry, June 2023). This technique achieves detection limits below 1 CFU/mL within minutes—significantly faster than conventional culture-based methods—opening avenues for point-of-care diagnostics.

Biofilm eradication studies published this year show synergistic effects when combining DTTB with chitosan derivatives—resulting formulations achieved complete eradication of mature biofilms formed by Mycobacterium tuberculosis (Nature Communications, April 2023). The combination enhances membrane permeabilization while chitosan's polycationic nature binds mycobacterial cell wall components synergistically improving penetration depth beyond conventional monotherapies.

New insights into molecular interactions were gained through single-molecule force spectroscopy experiments revealing how DTTB molecules bind specifically to negatively charged heparan sulfate proteoglycans on cancer cell surfaces—this selective targeting mechanism forms the basis for next-generation targeted drug delivery systems currently undergoing preclinical trials at Johns Hopkins University.

Safety profile advancements include new toxicity assessment protocols using CRISPR-edited human skin fibroblasts expressing fluorescent biosensors—these studies confirm reduced epidermal irritation potential compared to C?? analogues when applied topically below CMC levels (Toxicological Sciences, January 2023).

• 2650-53-5(Hexyltrimethylammonium bromide)
• 1943-11-9(Trimethyl(nonyl)azanium Bromide)
• 1119-97-7(Tetradecyltrimethylammonium bromide)
• 1120-02-1(Trimethyloctadecylammonium bromide)
• 19959-22-9(1-Dodecanamine,N,N-dimethyl-, hydrobromide (1:1))
• 57-09-0(Cetrimonium bromide)
• 2082-84-0(Decyltrimethylammonium bromide)
• 8044-71-1(Cetrimide)
• 2083-68-3(Trimethyloctylammonium bromide)
• 150-98-1(1-Pentanaminium,N,N,N-trimethyl-, bromide (1:1))